TOPLINE

Dupilumab improved nasal symptoms and quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), with benefits sustained through 24 months.

METHODOLOGY

• Researchers conducted a phase 4, prospective, global registry study across six countries to evaluate the long-term effectiveness and safety of dupilumab in adults with CRSwNP in a real-world setting.
• A total of 691 patients (mean age, 51.3 years; 55.7% men) were enrolled between 2021 and 2024 and monitored for up to 36 months, with no restrictions on dupilumab dosage or concomitant medications during the study period.
• Effectiveness was assessed via nasal congestion scores, loss-of-smell scores, Sino-Nasal Outcome Test scores, total symptom scores, University of Pennsylvania Smell Identification Test (UPSIT) scores, and Patient/Physician Global Assessment ratings; safety was assessed via treatment-emergent adverse events.

TAKEAWAY

• Nasal congestion scores decreased as early as 3 months, with improvements sustained through 24 months (change from baseline, -1.1; 95% CI, -1.3 to -0.9); similar improvements were observed in loss-of-smell scores (change from baseline, -1.3; 95% CI, -1.6 to -1.0) and Sino-Nasal Outcome Test scores (change from baseline, -18.0; 95% CI, -24.3 to -11.6).
• Similar improvements were seen in UPSIT scores and peak nasal inspiratory flow. The percentage of patients reporting “no symptoms” increased from 3.3% at baseline to 32.6% at 12 months and 42.9% at 24 months.
• Within the first 24 months, 23.9% of the patients reported at least one treatment-emergent adverse event, most commonly arthralgia, COVID, and injection-site reactions; no new safety signals were identified.

IN PRACTICE

“Dupilumab improved symptoms and HRQOL [health-related quality of life], with continuous improvements through 24 months’ follow-up, even in patients with coexisting type 2 inflammatory conditions,” the authors wrote.

SOURCE

Anju T. Peters, MD, with the Feinberg School of Medicine, Northwestern University, Chicago, was the corresponding author of the study, which was published online on July 27 in Annals of Allergy, Asthma & Immunology.

LIMITATIONS

The data for parameters such as UPSIT scores and peak nasal inspiratory flow values were either missing or incomplete, and sample sizes declined sharply at later timepoints. The study was not designed for formal hypothesis testing or powered to conduct subgroup analyses, and the absence of a control group limited causal inference.

DISCLOSURES

This study was sponsored by Regeneron Pharmaceuticals and Sanofi. Several authors, including the corresponding author, reported receiving research support, consulting, serving as members of advisory boards, or receiving speaker fees from multiple pharmaceutical companies; some authors reported being employees of or shareholders in Regeneron Pharmaceuticals or Sanofi. Detailed disclosures are noted in the original article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.